Cargando…

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells

Regardless of the recent groundbreaking introduction of personalized therapy, melanoma continues to be one of the most lethal skin malignancies. Still, a substantial proportion of patients either fail to respond to the therapy or will relapse over time, representing a challenging clinical problem. R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piotrowska, Anna, Beserra, Fernando Pereira, Wierzbicka, Justyna Marta, Nowak, Joanna Irena, Żmijewski, Michał Aleksander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740239/ https://www.ncbi.nlm.nih.gov/pubmed/35004285 http://dx.doi.org/10.3389/fonc.2021.763895

Ejemplares similares

Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line
por: Piotrowska, Anna, et al.
Publicado: (2019)

Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs
por: Piotrowska, Anna, et al.
Publicado: (2023)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors
por: Wasiewicz, Tomasz, et al.
Publicado: (2018)

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib
por: Bradford, James R., et al.
Publicado: (2013)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Albendazole repurposing on VEGFR-2 for possible anticancer application: In-silico analysis
por: Gaikwad, Nikita Maruti, et al.
Publicado: (2023)

Combined clinical features and MRI parameters for the prediction of VEGFR2 in hepatocellular carcinoma patients
por: Zhang, Laizhu, et al.
Publicado: (2022)

Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D(2) Against Human Malignant Melanoma Cell Lines
por: Piotrowska, Anna, et al.
Publicado: (2016)

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
por: Saleh, Nashwa M., et al.
Publicado: (2020)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
por: Shaldam, Moataz A., et al.
Publicado: (2023)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Distinct transcriptional responses of lymphatic endothelial cells to VEGFR-3 and VEGFR-2 stimulation
por: Dieterich, Lothar C., et al.
Publicado: (2017)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
por: Zhang, Ninggang, et al.
Publicado: (2022)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
por: Zimmer, Alexandra S., et al.
Publicado: (2019)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
por: Jinnin, Masatoshi, et al.
Publicado: (2008)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects
por: Chang, Yi-Wen, et al.
Publicado: (2014)

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
por: D'Haene, Nicky, et al.
Publicado: (2013)

Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex
por: Coon, Brian G., et al.
Publicado: (2015)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
por: Kühn, Clemens, et al.
Publicado: (2019)

The Effects of Vitamin D on the Expression of IL-33 and Its Receptor ST2 in Skin Cells; Potential Implication for Psoriasis
por: Wierzbicka, Justyna M., et al.
Publicado: (2021)

Extracellular Granzyme K Modulates Angiogenesis by Regulating Soluble VEGFR1 Release From Endothelial Cells
por: Li, Shuang, et al.
Publicado: (2021)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
por: Zhang, Qian, et al.
Publicado: (2020)

VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature
por: Liapi, Aikaterini, et al.
Publicado: (2021)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014)

TBX1 Represses Vegfr2 Gene Expression and Enhances the Cardiac Fate of VEGFR2+ Cells
por: Lania, Gabriella, et al.
Publicado: (2015)

VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis
por: Virtej, Anca, et al.
Publicado: (2016)

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
por: Szabo, Emese, et al.
Publicado: (2016)

Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy
por: Harris, Alexandra R., et al.
Publicado: (2022)

New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study
por: Al-Sanea, Mohammad M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7g4hjjcloro1smqik85n3mhlfk